Menu

Wolbachia-Laced Mosquitoes to Be Released for Population Control

The US government has approved the deployment of the lab-raised insects to eliminate the Zika- and dengue-transmitting Asian tiger mosquito.

Nov 7, 2017
Katarina Zimmer

Aedes albopictus ISTOCK, GORDZAMThe US Environmental Protection Agency (EPA) has given permission to a biotechnology startup to release mosquitoes into the environment that have been designed to eradicate wild populations of disease-carrying mosquitoes, Nature News reports.

The target is the Asian tiger mosquito Aedes albopictus, a vector for Zika virus—which began to spread in the U.S. last year—as well as dengue and yellow fever. The startup MosquitoMate has designed “killer” tiger mosquitoes by infecting males with the bacterium Wolbachia pipientis. When these treated males mate with wild female mosquitoes that don’t carry the same Wolbachia strain, the resulting eggs die.

According to Nature News, the EPA hasn’t officially announced the release of the insects yet, which will be limited to 20 states. These exclude the southeastern US states, despite harboring a greater concentration of mosquito populations, because field trials have not been conducted in those climates. Instead, the approved states are similar to New York, Kentucky, and California, where trials took place.  

MosquitoMate has launched a field trial of Wolbachia-treated mosquitoes in Florida, but with the A. aegypti species.

David O’Brochta, an entomologist at the University of Maryland, tells Nature: “It’s a non-chemical way of dealing with mosquitoes,” he says, “I’m glad to see it pushed forward, as I think it could be potentially really important.”

Designing lab mosquitoes to eradicate wild populations has been trialed multiple times in Brazil, which was hard hit by the Zika epidemic in 2015, and other countries. There, the company Oxitec has successfully tested modified A. aegypti mosquitoes—which also transmit Zika—such that a deadly gene will be passed on to any offspring once they mate in the wild. 

See “GM Mosquitoes Closer to Release in U.S.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.